Fulgent Therapeutics is working on a variety of new and improved treatments Read More
November 5, 2013 – Thank you to everyone that came by to talk with us at the 2013 ASHG conference in Boston, MA. An extra congratulations to Andrea Gropman who was the winner of our Ipad drawing. Come visit us at CCMG in Toronto, Canada and AMP in Phoenix, Arizona this month to get some more fun giveaways.
October 23, 2013 – Fulgent Therapeutics receives CAP (College of American Pathologists) accreditation. Joe Schramm from CAP stated, “The facility’s director Harry Gao, PhD, ABMG, was advised of this national recognition and congratulated for the excellence of the services being provided. Fulgent Therapeutics LLC Clinical Diagnostics Laboratory is one of more than 7,000 CAP-accredited facilities worldwide”.
October 18, 2013 – Congratulations to Jeffrey Bissonnette, winner of the Ipad drawing at the 2013 NSGC conference in Anaheim.
June 14, 2013 – Fulgent Therapeutics, a CLIA Certified Laboratory, announces the inclusion of the BRCA1 and BRAC2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets to its cancer risk assessment.
Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics and companion diagnostics. The Company has a number of improved generic and innovated drug candidates in its product pipeline for treating a broad range of cancers including breast, lung, ovarian, colon, and pancreatic cancers, along with new biomarker-based companion diagnostic tests.